For decades, Mariela Ayala lived under the weight of misdiagnosis—insomnia, depression, recurring infections, medication side effects, and steady weight gain. As prescriptions stacked up (25 at one point), she kept pushing, studying, and showing up for life. But everything changed when a perceptive psychiatrist ordered pharmacogenomic testing.

The results: an inherited MTHFR gene variant impacting folate activation which helps control many bodily functions like our metabolism, muscle structure and energy. With that insight, her team introduced methylated B12 and folate, a careful 90-day taper off unnecessary meds, and a return to real, culturally rich foods and herbs. Within weeks she felt energy and clarity return; blood pressure normalized; weight began to fall—ultimately 200 pounds lost holistically.

Today, Mariela is “Mari with the 411,” coaching high performers to rebuild identity and standards without abandoning culture. Her story is a rallying cry for patient advocacy, clinician awareness of PGx, and the power of precision medicine to change lives now—not someday.

Key takeaways

• Advocate for yourself: ask about pharmacogenomic testing and second opinions.
• Right form matters: methylated B vitamins and whole, culturally rooted foods supported Mariela’s turnaround.
• PGx testing can flag meds to avoid and guide safer, more effective care.

META DESCRIPTION

Meet Mariela Ayala, who spent 23 years treated for depression and insomnia but never felt well. A perceptive psychologist ordered a pharmacogenomic test and found an MTHFR variant that made it hard for her body to use folate. With answers at last, her plan shifted to methylated B12 and folate, a safe taper off 25 prescriptions, and fresh, flavorful foods from her culture. Within weeks her energy grew; within months her sleep, mood, blood pressure, and weight improved. Today Mariela coaches others to ask better questions, request the right tests, and build simple habits that fit real life. Her story shows how genetics can guide care, prevent years of trial-and-error, and turn fear into hope. Listen to celebrate her courage and learn how PGx can help you and your family. Genetics for Healthcare: A podcast for patients.

In this episode Kasey Walsh explains how simple social media connections grew into formal research collaborations, a nonprofit, and a patient‑owned data platform, all motivated by her determination to help her daughter Robbie, who was born with an AP-4 hereditary spastic paraplegia (AP‑4 HSP).

She has partnered with institutions like Boston Children's Hospital, the Broad Institute, and the University of Cambridge to move AP‑4 from case reports to research action.

Kasey co‑founded Cure AP‑4 and created WinSights to turn caregiver stories into research data that supports precision medicine. Her work helped find biomarkers, reclassify patients once thought to have cerebral palsy, and start drug‑repurposing studies that identified existing FDA‑approved medicines that showed activity in AP‑4 models.

She candidly shares their diagnostic journey to a diagnosis, tips for working with clinicians, and how families can help shape translational research.

Listeners who face a rare disease diagnosis will learn how to turn lived experience into real‑world evidence and join a community that helps accelerate precision medicine therapies for children and adults.

Key takeaways:

- Build community: online groups can lead to treatment opportunities and practical information to make daily life better for a family managing a rare disease.

- Own your data: patient‑stewarded health information powers precision medicine studies.

- Practical steps: seek genetic testing, connect with specialty centers, and link with advocacy groups (NORD, Global Genes).

META DESCRIPTION

Looking for hope after a rare disease diagnosis? Hear Kasey Walsh share how her daughter Robbie inspired partnerships with Boston Children's and the University of Cambridge to find treatment for AP-4 hereditary spastic paraplegia (AP-4 HSP). Learn how social media groups became real research teams, and practical steps families can take to find community, resources, and next actions to improve care for rare diseases. We help you learn the language and build confidence to advocate for a precision medicine approach to your health and wellbeing.

EPISODE SUMMARY

Rome experienced a career high talking with Dr. Otis W. Brawley, a globally recognized Medical Oncologist and Epidemiologist at the Johns Hopkins Kimmel Cancer Center, about his work to reduce healthcare disparities.

Dr Bawley is a former Chief Medical and Scientific Officer of the American Cancer Society, and an author on the recent Report on the Status of Disparities in the United States 2025.

Rome gets to the heart of why his work has shown that people do not always get the same care inside the health system. Dr Brawley says giving people access to care is not enough. Many patients still get later diagnoses, slower follow‑up, weaker or older treatments, and fewer chances to join clinical trials. These are real, measurable differences caused by provider choices and are at the root of cancer disparities.

Key takeaways from this in-depth conversation about disparities:

• Care that causes disparities differs in clear ways, including delays in diagnosis and treatment inequity.
• Why systemic changes to protocols and measuring clinician adherence beats simple training to deter differential treatment.
• Practical solutions like patient navigation and equity metrics to reduce preventable deaths.

META DESCRIPTION

What if a doctor’s choice—more than the cancer—decides who lives? Dr. Otis W. Brawley, a globally respected voice from the Johns Hopkins Kimmel Cancer Center, showed that black and brown patients often get worse care because doctors make different choices for them: fewer tests, slower follow‑up, less aggressive treatment, or no offer to join clinical trials. These choices come from wrong assumptions about what patients want, limits at busy or underfunded clinics, and they lead to later diagnoses and more deaths in communities of color. We need clear care rules, better tracking of who gets which treatments, and supports like patient navigation so decisions on the quality of care are fair for everyone.